Given the increasing number of patients with MPNST previously treated with MEKi for benign NF1-associated pNF and overlapping toxicity of co-targeting MEK and SHP2, a rationally designed alternate strategy involves targeting upstream RAS nucleotide cycling together with downstream effectors of ERK signaling. Here, NF1 is linked to malignant peripheral nerve sheath tumor.